Evaluation of safety and efficacy of docetaxel in the treatment of advanced hormone refractory prostate cancer under the conditions of daily practise.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
30
Docetaxel 75mg/m2/q3wx10 cycles with Prednisone 10mg/d/bid
Sanofi-Aventis
Prague, Czechia
PSA decline
Time frame: after each docetaxel administration and after the end of treatment
pain response
Time frame: after each docetaxel administration and after the end of treatment
side effects occurrence
Time frame: Throughout the study
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.